

Functional BAFF (human) Antibody, mAb (blocking)

Catalog # ADP0010

Specification

Functional BAFF (human) Antibody, mAb (blocking) - Product Information

Application IP

Reactivity Human

Host Purified From Concentrated Hybridoma

Tissue Culture Supernatant.

Clonality Monoclonal Isotype Rat IgG2a Gene Source Human

Application Note ,Functional Application, Inhibition of

human BAFF binding, IP(1:200)

Functional BAFF (human) Antibody, mAb (blocking) - Additional Information

Other Names

BLyS; TALL-1; CD257; B Cell Activating Factor; TNFSF13B

Target/Specificity

Recognizes human BAFF.

Format

Liquid. In PBS containing 10% glycerol and 0.02% sodium azide.

Reconstitution & Storage

Stable for at least 1 year after receipt when stored at -20°C.

Precautions

Functional BAFF (human) Antibody, mAb (blocking) is for research use only and not for use in diagnostic or therapeutic procedures.

Functional BAFF (human) Antibody, mAb (blocking) - Protein Information

Functional BAFF (human) Antibody, mAb (blocking) - Protocols

Provided below are standard protocols that you may find useful for product applications.

- Western Blot
- Blocking Peptides
- Dot Blot
- Immunohistochemistry
- Immunofluorescence
- <u>Immunoprecipitation</u>
- Flow Cytomety



• Cell Culture

Functional BAFF (human) Antibody, mAb (blocking) - Images

Functional BAFF (human) Antibody, mAb (blocking) - Background

BAFF is a master regulator of peripheral B cell survival, and together with IL-6, promotes Ig class-switching and plasma cell differentiation. BAFF co-stimulates activated T cells. Increased levels of soluble BAFF have been detected in the serum of patients with various autoimmune diseases, such as Sjögren's syndrome, rheumatoid arthritis, multiple sclerosis and systemic lupus erythematosus (SLE). Furthermore, BAFF is found in inflammatory sites in which there is lymphoid neogenesis. BAFF levels are elevated in patients with multiple myeloma and B cell chronic lymphoid leukemia (B-CCL).